Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers.

[1]  J. Jett,et al.  Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. Mitsudomi,et al.  Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  M. Volm,et al.  Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival , 2000, British Journal of Cancer.

[4]  T. Horie,et al.  Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. , 2000, European journal of cancer.

[5]  J. Muscat,et al.  K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. , 1999, Carcinogenesis.

[6]  E. Brambilla,et al.  Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF‐R1‐Flt1 and VEGF‐R2‐Flk1/KDR) in non‐small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival , 1999, The Journal of pathology.

[7]  M. Volm,et al.  Biological characterization of subgroups of squamous cell lung carcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  M. Higashiyama,et al.  A novel molecular staging protocol for non-small cell lung cancer , 1999, Oncogene.

[9]  H. Dosaka-akita,et al.  Bcl-2 Expression in Non-Small Cell Lung Cancers: Higher Frequency of Expression in Squamous Cell Carcinomas with Earlier pT Status , 1999, Oncology.

[10]  M. Rooney,et al.  Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Brousset,et al.  Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer , 1999, British Journal of Cancer.

[12]  W. Richards,et al.  Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Ishida,et al.  The prognostic significance of p53 and bcl‐2 expression in lung adenocarcinoma and its correlation with ki‐67 growth fraction , 1997, Cancer.

[14]  M. Buyse,et al.  Immunocytochemical markers in stage I lung cancer: relevance to prognosis. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Aktaş,et al.  Apoptosis bcl-2 and p53 expression and their relation to tumour stage in non-small cell lung carcinomas (NSCLC). , 1997, Cancer letters.

[16]  C. Angeletti,et al.  Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. , 1997, Journal of the National Cancer Institute.

[17]  S. Graziano.  Non-small cell lung cancer: clinical value of new biological predictors , 1997 .

[18]  J. Roh,et al.  Correlation between K‐ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma , 1997, Cancer.

[19]  S. Fox,et al.  Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. , 1996, European journal of cancer.

[20]  A. Ariza,et al.  Molecular staging of non-small cell lung cancer according to K-ras genotypes. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  J. Siegfried,et al.  Detection of K-ras mutations in lung carcinomas: relationship to prognosis. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  Y. Soini,et al.  Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. , 1995, Cancer research.

[23]  M. Wick,et al.  Expression of bcl-2 protein in stage T1NOMO non-small cell lung carcinoma , 1995 .

[24]  K. Yamamoto,et al.  Studies on clinicopathological features of lung cancer patients with K-ras/p53 gene alterations: comparison between younger and older groups. , 1995, Oncology.

[25]  C. Angeletti,et al.  Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. , 1995, British Journal of Cancer.

[26]  S. Rodenhuis,et al.  Comparative analysis of p53 gene mutations and protein accumulation in human non‐small‐cell lung cancer , 1995, International journal of cancer.

[27]  J. Izbicki,et al.  p53 in non-small-cell lung cancer. , 1994, Journal of the National Cancer Institute.

[28]  S. Steinberg,et al.  Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. , 1994, Cancer research.

[29]  U. Veronesi,et al.  The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. , 1994, Journal of the National Cancer Institute.

[30]  A. Harris,et al.  bcl-2 protein in non-small-cell lung carcinoma. , 1993, The New England journal of medicine.

[31]  A. Marchetti,et al.  p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. , 1993, Cancer research.

[32]  S. Goodman,et al.  Overexpression of the p53 Tumor Suppressor Gene Product in Primary Lung Adenocarcinomas Is Associated with Cigarette Smoking , 1993, The American journal of surgical pathology.

[33]  C. Angeletti,et al.  The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node‐negative non‐small cell lung cancer , 1992, Cancer.

[34]  K. Sugimachi,et al.  ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. , 1992, Cancer research.

[35]  S. Steinberg,et al.  ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. , 1991, Cancer research.

[36]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.

[37]  W. McGuire,et al.  Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors , 1990, Cancer.

[38]  S. Rodenhuis,et al.  Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. , 1988, Cancer research.

[39]  C. Mountain.  The new International Staging System for Lung Cancer. , 1986, The Surgical clinics of North America.

[40]  M. Gail,et al.  Prognostic factors in patients with resected stage I non‐small cell lung cancer. A report from the Lung Cancer Study Group , 1984, Cancer.

[41]  G W Moore,et al.  Prognostic factors in surgically resected limited-stage, nonsmall cell carcinoma of the lung , 1984, The American journal of surgical pathology.

[42]  D. Crowther,et al.  Cancer—Principles and Practice of Oncology. V , 1982, British Journal of Cancer.

[43]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[44]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[45]  J. Jassem,et al.  Prognostic relevance of proliferating cell nuclear antigen and p53 expression in non-small cell lung cancer. , 2002, Lung cancer.

[46]  T. Oyama,et al.  Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma. , 2000, Anticancer Research.

[47]  K. Sugimachi,et al.  K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. , 1997, British Journal of Cancer.

[48]  D. Jacobson,et al.  Molecular genetic tumor markers in the early diagnosis and screening of non-small-cell lung cancer. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  D. Harpole,et al.  A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. , 1995, Cancer research.

[50]  Rupert G. Miller,et al.  Survival Analysis , 2022, The SAGE Encyclopedia of Research Design.

[51]  A. Liebow.  Tumors of the lower respiratory tract , 1952 .